Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Fig. 3

Clearance-response analysis: a Nivolumab clearance (L/day) of a all patients receiving nivolumab monotherapy grouped by best overall response (BOR), and stratified by b NSCLC, c melanoma, and d RCC. Single measurements are represented by open circles. Bars indicate the 95% confidence interval of the mean. Abbreviations: progressive disease (PD), stable disease (SD) and partial response/ complete response (PR/CR). P-values indicated by *** < 0.001 (post-hoc independent samples t-test)

Back to article page